Clinical Trials Logo
  1. Home
  2. Ataxia Telangiectasia
  3. NCT05531890

Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjects

Ataxia Telangiectasia Clinical Trial

Official title:
Crossover Study to Evaluate the Comparative Bioavailability, Pharmacokinetics, and Safety of GTX-102 Administered as an Oral Spray Compared to Intramuscular Injection and an Oral Solution of Betamethasone in Healthy Subjects

Clinical Trial Summary

A Randomized, Open-label, Crossover Study to Evaluate the Comparative Bioavailability, Pharmacokinetics, and Safety of GTX-102 Administered as an Oral Spray Compared to Intramuscular Injection - betamethasone and an Oral Solution of Betamethasone in Healthy Subjects. Four groups of subjects will receive 2 treatments each and randomized in 2-way crossover.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05531890
Study type Interventional
Source Acasti Pharma Inc.
Contact
Status Active, not recruiting
Phase Phase 1
Start date September 13, 2022
Completion date May 3, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT02345135 - Susceptibility to Infections in Ataxia Telangiectasia N/A
Active, not recruiting NCT04991701 - A National Retrospective Population Based Cohort Study of the Natural History of Ataxia Telangiectasia
Recruiting NCT05692596 - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Completed NCT05252819 - Whole Body MRI for Cancer Surveillance in A-T
Recruiting NCT03357978 - Susceptibility to Infections, Tumor Risk and Liver Disease in Patients With Ataxia Telangiectasia N/A
Withdrawn NCT02309632 - Pancreatic Cancer Screening of High-Risk Individuals in Arkansas N/A
Not yet recruiting NCT06324877 - Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside N/A
Not yet recruiting NCT01075438 - Immunogenicity of Pneumococcal Vaccines in Ataxia-telangiectasia Patients N/A
Completed NCT03962114 - Effects of Vitamin B3 in Patients With Ataxia Telangiectasia Phase 2
Completed NCT04513002 - Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of Anaplerosis Phase 2
Completed NCT05471310 - Videoocular Assessment of Eye Movement Activity in an Ataxia Telangiectasia
Active, not recruiting NCT04870866 - NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia Phase 2
Recruiting NCT06193200 - To Evaluate the Effects of EryDex in Patients With A-T Phase 3
Recruiting NCT03563053 - Open-label, Long-term, Extension Treatment Using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients With Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study Phase 3
Recruiting NCT05692622 - Home-based Complex Intervention for Children With Ataxia Telangiectasia N/A
Recruiting NCT04037189 - Treatment of Leukemia and Lymphoma in Children With Ataxia Telangiectasia
Not yet recruiting NCT04887311 - MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia Phase 2
Active, not recruiting NCT00951886 - The Validity of Forced Expiratory Maneuvers in Ataxia Telangiectasia Studied Longitudinally N/A
Recruiting NCT03759678 - N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T) Phase 2
Recruiting NCT01052623 - Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT) Phase 4